550 related articles for article (PubMed ID: 25267524)
1. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
3. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M
BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib-induced thrombotic microangiopathy. A case report.
Scheggi V; Merilli I; Cesaroni E; Alterini B
J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
[TBL] [Abstract][Full Text] [Related]
6. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
Catanese L; Link K; Rupprecht H
BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
[TBL] [Abstract][Full Text] [Related]
7. [Carfilzomib in multiple myeloma relapses].
Bay JO
Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287
[No Abstract] [Full Text] [Related]
8. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
12. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
[TBL] [Abstract][Full Text] [Related]
13. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J
Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313
[TBL] [Abstract][Full Text] [Related]
15. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Khan ML; Reeder CB; Kumar SK; Lacy MQ; Reece DE; Dispenzieri A; Gertz MA; Greipp P; Hayman S; Zeldenhurst S; Dingli D; Lust J; Russell S; Laumann KM; Mikhael JR; Leif Bergsagel P; Fonseca R; Vincent Rajkumar S; Keith Stewart A
Br J Haematol; 2012 Feb; 156(3):326-33. PubMed ID: 22107129
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma, version 1.2013.
Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Illizaliturri F; Huff CA; Kassim A; Krishnan AY; Liedtke M; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Weber D; Yahalom J; Yunus F; Shead DA; Kumar R
J Natl Compr Canc Netw; 2013 Jan; 11(1):11-7. PubMed ID: 23307977
[TBL] [Abstract][Full Text] [Related]
17. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
[TBL] [Abstract][Full Text] [Related]
18. [Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy].
Fujimori C; Hagino T; Osanai S; Sano S; Saga R; Hidai H; Kurimoto M; Murai Y; Akiyama H; Motomura S
Rinsho Ketsueki; 2022; 63(12):1626-1632. PubMed ID: 36653134
[TBL] [Abstract][Full Text] [Related]
19. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
20. Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.
Cassol CA; Williams MPA; Caza TN; Rodriguez S
Medicine (Baltimore); 2019 Sep; 98(39):e17148. PubMed ID: 31574818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
